86 related articles for article (PubMed ID: 26504016)
21. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Wu SQ; Xu ZZ; Niu WY; Huang HB; Zhan R
Int J Mol Med; 2014 Aug; 34(2):616-23. PubMed ID: 24913180
[TBL] [Abstract][Full Text] [Related]
22. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
[TBL] [Abstract][Full Text] [Related]
24. Azole antifungal agents related to naftifine and butenafine.
Castellano S; La Colla P; Musiu C; Stefancich G
Arch Pharm (Weinheim); 2000 Jun; 333(6):162-6. PubMed ID: 10909187
[TBL] [Abstract][Full Text] [Related]
25. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
26. Anti-proliferative effect of levamisole on human myeloma cell lines in vitro.
Ramanadham M; Nageshwari B
J Immunotoxicol; 2010; 7(4):327-32. PubMed ID: 20860474
[TBL] [Abstract][Full Text] [Related]
27. Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines.
Kumagai T; Müller CI; Desmond JC; Imai Y; Heber D; Koeffler HP
Leuk Res; 2007 Apr; 31(4):523-30. PubMed ID: 17007926
[TBL] [Abstract][Full Text] [Related]
28. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
30. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
31. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
33. [Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):234-7. PubMed ID: 18843976
[TBL] [Abstract][Full Text] [Related]
34. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
36. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
37. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
[TBL] [Abstract][Full Text] [Related]
40. Reversible naftifine-induced carotenoid depigmentation in Rhodotorula mucilaginosa (A. Jörg.) F.C. Harrison causing onychomycosis.
Moț AC; Pârvu M; Pârvu AE; Roşca-Casian O; Dina NE; Leopold N; Silaghi-Dumitrescu R; Mircea C
Sci Rep; 2017 Sep; 7(1):11125. PubMed ID: 28894295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
